

C1

MarkPap@ Products™ and Services(sm)

MarkPap Test Reagent Kit

This is a set of reagents, control and instructions for processing specimens, which is accurate, affordable, simple and may be performed by a low-trained technician at the Point-of Care. This will dramatically increase the number of locations where specimens can be processed.

MarkPap Telemedicine Service

For diagnosis at distance (telectytopathology), capturing and transmitting images digitally or by cell phone to a specialist for final diagnosis. This will eliminate the need for local infrastructure.

MarkPap@ Self-collection Home Kit

The kit is to allow women to easily take sample at home and send it to the laboratory for testing. This is to help women who do not have access to doctor's offices, are not allowed or are uncomfortable to visit gynecologist and have a pelvic exam.



MARKPAP INDIA, LLC

Contact: Prof. Dr. N. Markovic, President & CEO

Ph. 301-610-9130

e-mail: info@bioscicon.com

9700 Great Seneca Hwy
Suite 149
Rockville, MD 20850

Website: www.bioscicon.com
© BioSciCon, 2012




MarkPap India,
LLC

FIGHTING CERVICAL CANCER

IS THIS NECESSARY TO BE SO? NO!

INDIAN NEEDS
COMPARED WITH US AND CHINA



If not prevented. . .




Now, is too late!

MARKPAP® PLATFORM TECHNOLOGY IS AVAILABLE




MarkPap India, LLC is a small business incorporated in 2010 in the State of Maryland, USA. It is organized as a whole sale, trade organization with a mission to commercialize BioSciCon's MarkPap@ platform technology products and services in India.

Web Site: www.bioscicon.com



MOBILE TELECYTOTOLOGY

CERVICAL CANCER PREVENTION IN INDIA




Legend: Dysplastic cell + HPV disease

Cervical cancer is major health problem in India. According to Indian statistics, more than 70,000 women's lives are lost annually and the prognosis is even worse because of projected increase of 150% of mortality and morbidity between 2010 and 2025.

Since cervical cancer is completely preventable disease, if detected on time, the reason for this situation is a very low outreach for preventive screening, which is only 6% in India. It means that out of 300 million women at risk for cervical cancer only less than 20 million women are protected and 280 million, mostly in the rural areas, are left behind.

We think that India needs new strategy and new tools like our proprietary biomarker-based, telemedicine powered, infrastructure independent, MarkPap platform Technology. It consists of tools, products, services, procedures, quality controls, medical diagnostic protocols and digital and wireless imaging to enable Indian healthcare providers to reach this goal.

COMPREHENSIVE STRATEGY TO REVERSE CERVICAL CANCER PREVALENCE AND MORTALITY



WHAT YOU CAN DO WITH OUR TOOLS

This graph presents the new strategy. At the outreach of 50%, the trends for cervical cancer prevalence and mortality will start to decrease.

How to increase the outreach? MarkPap India, LLC offers three products/services to achieve this goal: